POPULARITY
Categories
22 episodes with GSK
37 episodes with GSK
22 episodes with GSK
19 episodes with GSK
16 episodes with GSK
17 episodes with GSK
16 episodes with GSK
10 episodes with GSK
7 episodes with GSK
11 episodes with GSK
17 episodes with GSK
8 episodes with GSK
11 episodes with GSK
7 episodes with GSK
7 episodes with GSK
6 episodes with GSK
8 episodes with GSK
9 episodes with GSK
9 episodes with GSK
6 episodes with GSK
5 episodes with GSK
5 episodes with GSK
9 episodes with GSK
7 episodes with GSK
6 episodes with GSK
3 episodes with GSK
6 episodes with GSK
4 episodes with GSK
4 episodes with GSK
6 episodes with GSK
8 episodes with GSK
5 episodes with GSK
2 episodes with GSK
3 episodes with GSK
6 episodes with GSK
3 episodes with GSK
5 episodes with GSK
5 episodes with GSK
3 episodes with GSK
3 episodes with GSK
3 episodes with GSK
6 episodes with GSK
3 episodes with GSK
5 episodes with GSK
5 episodes with GSK
6 episodes with GSK
3 episodes with GSK
6 episodes with GSK
3 episodes with GSK
3 episodes with GSK
4 episodes with GSK
6 episodes with GSK
3 episodes with GSK
3 episodes with GSK
Astma je jedno z nejčastějších chronických onemocnění dýchacích cest, a přesto ho často podceňujeme. S pneumologem prof. MUDr. Milanem Sovou, Ph.D., si povídáme o tom, jak astma vzniká, proč hraje roli genetika i prostředí, a jak vypadá moderní léčba.Dozvíš se, kdy je čas vyhledat specializované centrum pro těžké astma, proč užívání systémových kortikoidů není dlouhodobě ideální a jaké výhody má biologická léčba, kterou si pacient může aplikovat sám.V timestamps si můžeš vybrat konkrétní téma, které tě zajímá:▬▬▬▬▬▬▬▬▬▬ Timestamps ▬▬▬▬▬▬▬▬▬▬00:00 Intro a představení hosta01:06 Jak probíhá práce na Klinice nemocí plicních a tuberkulózy ve Fakultní nemocnici v Brně03:40 Co je to astma05:39 Jak je na tom ČR s astmatem09:28 Co je to těžké astma a čím se liší od klasického12:24 Jakou roli hraje genetika 15:05 Základní pilíře léčby astmatu17:50 Kortikoidy a astma20:50 Biologická léčba astmatu26:30 Proč je důležité dostat se včas do specializovaného centra léčby těžkého astmatu
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. During a Senate hearing, Robert F. Kennedy Jr. faced criticism for spreading anti-vaccine views and breaking promises regarding vaccines. The FDA released rejection letters for companies like Lykos Therapeutics, Stealth Biotherapeutics, and Regeneron. Ousted CDC director Susan Monarez accused Kennedy of firing her for not supporting Covid-19 recommendations from an advisory panel with "antivaccine rhetoric." Hengrui Pharmaceuticals signed lucrative deals with Merck and GSK, while the FDA promised to release future Complete Response Letters promptly. In other news, Sanofi's anti-OX40 blocker failed in a Phase III study, Gilead partnered with the US State Department for low-income countries, and AC Immune announced workforce cuts. Kennedy was accused of lying during the hearing, and the FDA released a new rare disease approval framework.
We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer.The team's idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024.Robin outlines Myricx's journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for him.--------------------This episode is sponsored by Kadans. Learn more about Kadans' London Innovation Centre where life sciences companies grow from start-up to global player: https://bit.ly/kadans-myricxbio--------------------⭐️ ABOUT THE SPEAKERRobin kicked off his Myricx experience as chief development officer in November 2019, before rising to the CEO seat in August 2022. Before this, he was VP of drug discovery at Astex Therapeutics, before spending more than a decade in research executive roles at GSK. ending up as SVP Drug Design and Selection.
For a captioned version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-15-pkpd-drug-discovery/In this episode of the Pharmaron DMPK Insights Podcast Series, Simon Taylor and Dr. Emile Chen discuss the relationship of drug concentration and effect (PKPD). PKPD is critical to decision making from initial modality selection, through molecule optimization, translational science and clinical dosage planning. Simon and Emile discuss the concepts and practical applications of PKPD and explore the concept of model-based target pharmacology assessment in combination with physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) modelling to improve decision making.** Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery”, J Med Chem. 2021 Mar 25;64(6):3185-3196. We will address the following points: What is PKPD and its importance throughout a discovery project lifecycle How PKPD can be used to guide decision making including case study examples How a combination of physiologically based pharmacokinetic/ pharmacodynamic (PBPK/PD) modeling and machine learning (ML) can be used to elucidate the optimal combination of properties for the targeted pharmacology Our Moderator:Simon Taylor – Vice President, Drug Discovery at Pharmaron Simon Taylor is Vice President of Drug Discovery and is based in Hoddesdon, UK. With over 27 years of industry experience, he is responsible for DMPK/ADME and PKPD strategy, including human extrapolation and PBPK modelling and simulation, for Pharmaron's integrated drug discovery projects from early discovery through to IND submission. Before Pharmaron, Simon worked at GSK for 20 years, leading DMPK and Quantitative Pharmacology teams and projects from the Hit Identification stage through to the clinic. He has worked across respiratory, inflammation, oncology, and cardiovascular therapy areas with drugs of varying routes of administration. Simon has a BSc in Pharmacology from the University of Leeds and an MSc in Model Based Drug Development from the University of Manchester. He has co-authored over 30 scientific publications in the literature. Our Speakers:Dr. Emile Chen – Formerly Director, Modeling and Translational Biology at GlaxoSmithKline Dr. Emile Chen has thirty years of industrial experience divided between early discovery involved in lead optimization and candidate selection, and late-stage development, including authoring and reviewing of regulatory documentation and NDA submission. Until March 2024, he was in the System Modeling and Translational Biology group, using PBPK, Mechanistic PKPD modeling, QSP, and machine learning techniques to solve project questions and thereby enhance scientific productivity. Emile received his undergraduate degree from the University of California, Los Angeles, and his PhD from Northwestern University in the field of Biomedical Engineering, specializing in the development of mathematical models for information processing in the brain. He began his pharmaceutical career at Hoffmann-La Roche in 1993, following a postdoctoral fellowship at the University of California, San Francisco. He joined GlaxoSmithKline in 1996. Over the years, he has led ADME and PK groups at various times, supporting both early discovery and late development DMPK efforts. More recently, rStay tuned for more podcasts in our Pharmaron DMPK Insights Series!
In this episode of Future Fuzz, we sit down with Darius Meadon, Chief Marketing Officer at OWKIN, one of Forbes and Sequoia Capital's top 50 AI companies. OWKIN is pioneering the use of agentic AI and multimodal data in healthcare to accelerate diagnostics and drug discovery. Darius shares how his team communicates complex science to biotech and pharma clients, why video content and personalization are crucial in modern B2B marketing, and what it takes to build long-term trust in the highly regulated world of healthcare innovation.From live demos that stop traffic at global conferences to AI-powered personalization strategies, Darius reveals the mindset and tools that drive engagement and growth in a challenging sector. This episode is a must-listen for marketers, healthcare innovators, and tech leaders aiming to scale with science.Guest BioDarius Meadon is the Chief Marketing Officer at OWKIN, an agentic AI company on a mission to decode complex biology and accelerate the development of life-saving treatments and diagnostics. OWKIN's work spans cutting-edge areas such as spatialomics, proteomics, and multimodal data fusion. Prior to OWKIN, Darius built a robust career in marketing, brand strategy, and innovation with global giants like GSK, Bayer, Unilever, and Coca-Cola.With a Master's in Science from Oxford and further studies at Harvard, Darius blends scientific depth with marketing expertise. He's a passionate advocate for science communication, video-led storytelling, and smart segmentation strategies to cut through in a complex, regulated B2B space.TakeawaysPersonalization must align message, format, and channel to buyer pain pointsVideo is essential: explainer content, product sizzles, and authentic team videos all build engagementIn-person events demand standout visuals, live demos, and smart giveawaysFounder-led content can drive authenticity and start bold conversationsAI-powered tools like LLMs enable real-time product demos that resonate deeply with usersLong sales cycles in pharma require a robust, multi-touch, 360-degree marketing approachLinkedIn newsletters outperform email for engagement in saturated inboxesChapters00:00 Welcome and Intro to Darius Meadon 01:00 The Origin Story of OWKIN 02:10 Using AI to Diagnose and Predict Cancer Outcomes 03:45 Breaking Down Biology Complexity for Drug Discovery 05:20 How to Simplify Science for Sophisticated Buyers 06:40 The Power of Video in B2B Healthcare Marketing 07:50 Smart Segmentation and Multi-Touch Engagement Strategy 09:00 Navigating Long Sales Cycles in Pharma 10:10 Creating Demand Before Product Launches 11:00 Founder-led Content and Balancing Authenticity with Brand 12:20 How OWKIN Uses LinkedIn to Scale Thought Leadership 15:00 Thoughts on Personalization and Agentic AI 20:00 Matching Buyer Pain Points with the Right Channel and Format 24:00 How OWKIN Stands Out at Large Conferences 26:00 From Plushies to Illustrated Booklets: Smart Giveaways that Stick 28:30 Closing Thoughts and Where to Connect with DariusLinkedInFollow Darius Meadon on LinkedIn here : Follow Justin Campbell on LinkedIn here :
Daniel Snell, co-founder and management consultant at Arrival, works with senior leaders of large PLCs, including Tesco, Investec, Sky, GSK and Morgan Stanley, and helps other founders to refocus on what they usually got into business for, and going back to the basics of productivity, performance and growth. In this podcast we talk about opportunity, potential and why happiness and productivity are not mutually exclusive... Hosted on Acast. See acast.com/privacy for more information.
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well." #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer actuatetherapeutics.com Download the transcript here
Dan Schmitt, President and CEO of Actuate Therapeutics, is developing a cancer therapy that inhibits GSK3β, a key enzyme that is hijacked in cancer cells to drive tumor growth. Inhibiting this enzyme can impact the cancer cells and stimulate an immune response against the tumor. Actuate selected metastatic pancreatic cancer as their first target due to unmet need and promising data for their lead drug candidate. This could represent a significant advancement in the treatment of metastatic pancreatic cancer, offering a new standard-of-care option. Dan explains, "So, GSK-3β is a known quantity across a number of inflammatory diseases. It was understood when we first started the company that, particularly in cancer cells, GSK is hijacked in its activity. Basically it's been shown that in normal cells, GSK-3β sits in the cytoplasmic domain and there it's involved in multiple paths, basically in glucose metabolism. But in cancer cells, it translocates into the nuclear compartment, and there it's accumulated at much higher levels and then sits upstream of a pro-oncogenic set of pathways, all mediated by NF-κB. NF-κB is notorious in cancer. It regulates gene expression involved in tumor growth and progression, chemoresistance, and protects tumor cells from death." "So it's been very difficult to target NF-κB directly, but we can target GSK-3β directly, specifically and potently, and therefore downregulate those key oncogenic processes. And that's really where we started the company, that set of activities of this protein. What's been shown since we've been in the clinic is that there is also a resulting upregulation of immune response from the host towards the cancer itself based on this inhibition of GSK-3β as well." #ActuateTherapeutics #Cancer #PancreaticCancer #MetastaticPancreaticCancer actuatetherapeutics.com Listen to the podcast here
In this Healthed lecture, Professor Hubertus Jersmann will explain, spirometry, as done in general practice, enables accurate and early detection of COPD, and could be utilised more often to identify the many people who have this condition but remain undiagnosed or misdiagnosed. In addition, he will present the practical considerations of performing spirometry in the primary care setting - the logistics, the contraindications, the interpretation of results as well as common pitfalls and challenges. This educational activity was developed by Healthed at the request of and with funding from GSK.See omnystudio.com/listener for privacy information.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TTF865. CME/MOC/AAPA credit will be available until August 30, 2026.Building Confidence in RSV Vaccination: Addressing Vaccine Hesitancy and Inequities in At-Risk Populations In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PAT865. CME/MOC/NCPD/AAPA/IPCE credit will be available until August 10, 2026.The Power Sequence in RRMM: Collaborative Approaches for Optimizing Sequential Treatment With Cellular and Off-the-Shelf Immunotherapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This episode covers: Cardiology This Week: A concise summary of recent studies Oral anticoagulation in atrial fibrillation: answers to frequent questions Smartwatch, heart rate and ECG Milestones: Lyon Diet Heart study Host: Emer Joyce Guests: Carlos Aguiar, Tim Chico, Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Paulus Kirchhof has declared to have potential conflicts of interest to report: partially supported by European Union MAESTRIA (grant agreement 965286), British Heart Foundation (AA/18/2/34218), German Center for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, grant numbers DZHK FKZ 81X2800182, 81Z0710116, and 81Z0710110), German Research Foundation (Ki 509167694), Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, and the Else-Kröner-Fresenius Foundation. Research support for basic, translational, and clinical research projects from German Research Foundation (DFG), European Union, British Heart Foundation, Leducq Foundation, Else-Kröner-Fresenius Foundation, Dutch Heart Foundation (DHF), the Accelerating Clinical Trials funding stream in Canada, Medical Research Council (UK), and German Center for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last five years. Listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Emer Joyce Guest: Tim Chico Want to watch that extended interview on smartwatch, heart rate and ECG? Go to: https://esc365.escardio.org/event/1811?resource=interview Want to watch that episode? Go to: https://esc365.escardio.org/event/1811 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Tim Chico has declared to have potential conflicts of interest to report: research funding from Google. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Ready to transform your HR operations?Download Deel's free AI-powered HR guide and discover how to streamline processes, stay compliant, and scale globally with ease: https://shorturl.at/Y1ySBWhy do toxic workplaces thrive, and how can leaders turn them around? In this HR L&D Podcast episode, we're sitting down with Dr Mary-Clare Race, a workplace psychologist and leadership expert, to uncover the psychology of toxic cultures and the strategies that transform them into thriving, inclusive environments.From her PhD research to leading DE&I initiatives for companies like Barclays, GSK, and Unilever, Dr Race explains why harmful behaviors persist, how to rebuild belonging, and why empathy, resilience, and self-awareness are the hallmarks of great leadership. She shares practical ways to hold leaders accountable, strengthen workplace connection, and use AI as a tool to support human-centered coaching.Whether you're in HR or lead a team, this conversation delivers actionable insights for creating healthier, more productive workplaces.Dr Mary-Clare Race's LinkedIn: https://www.linkedin.com/in/dr-mary-clare-race-b59a602/Nick Day's LinkedIn: https://www.linkedin.com/in/nickday/Find your ideal candidate with our job vacancy system: https://jgarecruitment.ck.page/919cf6b9eaSign up to the HR L&D Newsletter - https://jgarecruitment.ck.page/23e7b153e7(00:00) Why Human Resources Matter Most (01:46) Introducing Dr Mary-Clare Race (04:00) The Psychology of Workplace Toxicity (06:06) The “Toxic Triangle” Explained (07:48) Turning Toxic Cultures Into Thriving Ones (10:40) Why DE&I Slips During Economic Pressure (13:16) The Backlash Against DE&I (15:12) Building Belonging Through Human Connection (16:45) Remote Work's Impact on Toxicity (18:27) The Connection Crisis at Work (22:19) Do Playground Bullies Become Business Leaders? (26:25) How Early Experiences Shape Leadership Styles (28:56) Empathy, Resilience & Self-Awareness in Leadership (31:46) Micro-Coaching Moments for Busy Leaders (33:30) Leading Multi-Generational Workforces (36:42) Supporting Caregivers and Working Parents (39:26) AI in Coaching and Leadership Development (43:45) Final Advice for HR Leaders
Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD's guests this season, uncovering the challenges and opportunities shaping today's pharmaceutical industry. From self-advocacy at work and the future of personalised medicine to disease awareness, market access and making your marketing efforts stand out – they explore the season's core themes, all backed by the latest industry data. Watch our featured guest's full episodes: GSK's Dheepa Chari on the evolving sphere of scientific communication Yacin Marzouki on disrupting the traditional omnichannel model BMS' Anita Gandhi on a decade of change in hematology Pfizer's Richard Maughan on the future of access in the UK GSK's Matt Mortimer-Ryan on behaviour-led pharma marketing Chiesi's Shish Patel on COPD, the climate and improving care AbbVie's Dr Daejin Abidoye on community and compassion in cancer care Bayer's Dr Joana Reis on the promise of AI in breast cancer
Sue Norfolk, manager of the Schroder Income Growth Trust, shares how UK companies are adapting their capital distribution strategies with a shift towards share buybacks and stable dividend growth. We also cover the evolving landscape of domestic versus international opportunities, sector-specific insights into financials, consumer discretionary, and industrials, and how geopolitical tensions are factored into portfolio decisions. Finally, we examine the fund's bottom-up stock selection approach, recent adjustments in holdings like AstraZeneca, GSK, and Burberry, and the current valuation-driven opportunities in the market.What's covered in this episode:Schroder Income Growth's dividend hero statusDividends, share buybacks or social dividends?How volatility is factored into the portfolioStaying focused on bottom-up stock pickingThe impact of US politics on the trustRight and wrong tariff callsThe attractive nature of UK mid-capsA closer look at financials and customer discretionaryMaking calls on defence and industrialsWhy this manager favours AstraZeneca over GSKDoubling down on BurberryWhy UK equity is still attractive todayMore about the trust: Launched in 1995, the Schroder Income Growth Trust's principal aim is to provide real growth of income in excess of the rate of inflation. It invests mainly in the shares of UK larger and medium-sized companies, although it can also invest some of the portfolio in the shares of firms listed abroad.Learn more on fundcalibre.comPlease remember, we've been discussing individual companies to bring investing to life for you. It's not a recommendation to buy or sell. The fund may or may not still hold these companies at the time of listening. Elite Ratings are based on FundCalibre's research methodology and are the opinion of FundCalibre's research team only.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete NCPD information, and to apply for credit, please visit us at PeerView.com/ZNS865. NCPD credit will be available until July 29, 2026.Leading the Next Chapter of Myeloma Care: Oncology Nurse Stewardship in the Era of Innovative Antibodies and Cellular Therapies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by independent medical education grants from AbbVie, GSK, and Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This episode covers: Cardiology this Week: A concise summary of recent studies Atrial fibrillation in heart failure Temperature management following cardiac arrest Statistics Made Easy: Collider bias Host: Emer Joyce Guests: Carlos Aguiar, Christian Hassager, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/1812 Want to watch that extended interview on temperature management following cardiac arrest? Go to: https://esc365.escardio.org/event/1812?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Emer Joyce Guest: Christian Hassager Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1812?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1812 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests Stephan Achenbach, Emer Joyce, Christian Hassager, Nicolle Kraenkel and Theresa McDonagh have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Vinay Prasad's departure from CBER has analysts anticipating a more traditional successor, while GSK streamlines its pipeline and pledges billions in US investments. Susan Monarez is now the confirmed CDC director, and the top biopharma venture capital raises of H1 2025 are summarized. Despite challenges like layoffs and market fluctuations, GSK remains committed to investing in the US despite tariffs. Other headlines include Madrigal's potential $2 billion investment, Biogen and Eisai's Alzheimer's drug update, and Novo Nordisk's new leadership. Trilink Biotechnologies is offering self-amplifying RNA constructs for potential therapeutic advancements.AI biotech companies have secured substantial funding in the first half of 2025, with continued investment pouring into startups within the industry. The top five biopharma venture capital raises of this period are highlighted. There is confusion surrounding Ira's definition of 'drug,' potentially hindering companies from pursuing approval for new formulations and indications. Vinay Prasad's departure from the FDA's Center for Biologics Evaluation and Research, following controversies related to Sarepta, has raised concerns among developers. Despite challenges, four biotech companies are successfully launching their products independently.Over 260 million people are impacted by rare diseases, emphasizing the need for faster evidence generation through global real-world data. GSK's commitment to investing in the US, Merck's cost-cutting measures to support its launch schedule, and Novo Nordisk's new leadership are also highlighted. The FDA has updated regulations regarding Sarepta's DMD gene therapy, making it available for ambulatory patients. Adaptimmune anticipates significant staff reductions following a cell therapy asset sale. Stay tuned for more updates on the latest developments in the biopharma industry.
US Treasury Secretary Bessent said he will see US President Trump regarding the China tariff pause on Wednesday and some technical details remain on the China tariff pause, while the China tariff extension decision will be up to Trump and if he does not approve tariff pause extension, tariffs on Chinese goods would 'boomerang' back to April 2nd levels, or another level that he chooses.US President Trump said Chinese President Xi wants to meet and he thinks it will happen before the end of the year, while he stated that they will either approve the trade extension or not. Chinese Vice Commerce Minister Li said the US and China have agreed to extend the trade truce; Bessent said China jumped the gun a little on the 90-day pause.Crude futures surged yesterday amid comments from US President Trump who confirmed changing the deadline for Russia to reach a Ukraine ceasefire agreement to 10 days, while there were simultaneous comments from Treasury Secretary Bessent who told Chinese officials that China could face high tariffs if it continues to purchase sanctioned Russian oil due to US secondary tariff legislation.APAC stocks traded mixed following the subdued handover from Wall St; European equity futures indicate a mildly positive cash market open with Euro Stoxx 50 futures up 0.3% after the cash market closed with gains of 0.8% on Tuesday.Looking ahead, highlights include French GDP, Spanish CPI, German GDP & Retail Sales, Italian GDP, ECB Wage Tracker, EZ GDP & Sentiment, US ADP National Employment, GDP Advance (Q2), PCE (Q2), Fed, BoC, BCB Policy Announcements Speakers including Fed Chair Powell, BoC's Macklem & Rogers, Supply from Italy, US Quarterly Treasury Refunding Announcement.Earnings from Hermes, Airbus, Vinci, Danone, Capgemini, HSBC, GSK, Aston Martin, Santander, Caixabank, Telefonica, Intesa Sanpaolo, Leonardo, Mercedes Benz, Siemens Healthineers, BASF, Adidas, Porsche AG, Meta, Microsoft, RobinHood, Carvana, Lam Research, Qualcomm, Ford, Arm, eBay, FMC, Vertiv, Altria, Kraft Heinz, GE Healthcare & VF Corp.Read the full report covering Equities, Forex, Fixed Income, Commodites and more on Newsquawk
This week's deal between GSK and Jiangsu Hengrui is a prime example of how Western biopharmas have begun to recognize the innovation and opportunities being fostered in China — and how it's no longer all about fast followers.On the latest BioCentury This Week podcast, BioCentury's analysts put the collaboration between GSK and Jiangsu Hengrui Pharmaceuticals, two of the most active cross-border dealmakers, into the context of East-West dealmaking over the past 30 months, assessing the innovation that is driving the rush to partner with biotechs in China, Japan, South Korea and beyond, and the types of companies looking to Asia for assets.BioCentury's analysts also discuss Steve Bates' outsized role in building the U.K. biotech hub, as he readies to take on a new role in the U.K. government. They examine new VC funds from Omega Funds and Brandon Capital, FDA's new national priority voucher pilot program, and fallout from how FDA and Sarepta Therapeutics handled the deaths of four patients who had received the biotech's gene therapies. This episode of BioCentury This Week is sponsored by IQVIA Biotech.View full story: https://www.biocentury.com/article/656592#biotech #biopharma #pharma #lifescience #EastWestDealmaking #ChinaBiotech #UKBiotech #FDAPolicy00:01 - Sponsor Message: IQVIA Biotech02:48 - Asia Deals Landscape17:32 - Steve Bates & U.K. Biotech25:46 - FDA's New Voucher Pilot31:01 - New VC Funds35:28 - SareptaTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. GSK has entered a partnership with Hengrui worth up to $12 billion, focusing on the COPD candidate HRS-9821. The FDA's new voucher policy has caused confusion among experts, as it lacks clear definition and was announced without public input. The American Medical Association urges RFK Jr. to maintain the preventive task force, and Sarepta denies a patient death is linked to Elevidys as the FDA launches a probe. Biopharma companies are leaning towards holistic treatments for Alzheimer's, while Atai-partnered schizophrenia drug fails in a mid-stage trial. Boehringer partners with Irish startup Re-Vana in a $1 billion+ eye deal.As the Alzheimer's space becomes more competitive, biopharma companies are focusing on holistic treatments beyond disease-modifying drugs like Leqembi and Kisunla. Companies such as Bristol Myers Squibb, Acadia, Otsuka, and Lundbeck are renewing their search for symptomatic treatments. Five upcoming data drops could potentially lead to more effective therapies for Alzheimer's. Sarepta Therapeutics is facing challenges due to safety concerns surrounding its gene therapies, leading to a drop in stock value. The FDA's new voucher program aims to offer accelerated pathways for drugs meeting certain criteria, but experts criticize the lack of transparency and public input in the policy's announcement. Sarepta's future is uncertain as the FDA considers a new study for Elevidys, and the EU issues a negative opinion on the drug. Other news includes delays in the FDA decision on GSK's Blenrep, AstraZeneca's PIII win with nanobody treatment for myasthenia gravis, and the removal of thimerosal from influenza vaccines. George Tidmarsh has been appointed as the new chief of FDA's CDER.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Roche has dropped an early-stage obesity asset, CT-173, citing lack of competitiveness. Novartis has entered into a drug discovery deal with Matchpoint Therapeutics, acquiring global rights on all molecules for several inflammatory diseases. AstraZeneca claims a Phase III win with its nanobody treatment for myasthenia gravis. Second-quarter earnings season is approaching, and biotechs to watch include Sarepta and others facing challenges in the biopharma industry. Genentech downsizes as priorities shift, and GSK's comeback for Blenrep is on pause as the FDA delays its decision. The FDA's lack of transparency has tarnished Sarepta's reputation after patient deaths triggered an FDA battle. Opportunities in the industry include roles like Quality Specialist at CSL and Clinical Research Physician at Eli Lilly and Company.
During the Asia-focused Episode 29 of Biotalk, Geoff shares insights into key trends and developments shaping the biotech landscapes in Japan, China, Korea, Australia, and the broader Asia-Pacific region, as featured in our 2025 Q2 Report: Global Trends in Biopharma Transactions Report. Japan's biotech stocks outperformed broader indices, boosted by regulatory reforms and Shionogi's $1.1B acquisition of Japan Tobacco's pharma units. Licensing slowed, while early-stage financings focused on preclinical firms. China's biotech market surged with four HKEX IPOs raising $1.5B. Venture funding fell as risk aversion grew, but strategic licensing stayed strong at $24.4B, shifting toward later-stage oncology and obesity deals. Korea's biotech index dipped but showed 12-month gains, driven by ABL Bio's $2.8B licensing deal with GSK and key Series B financings. Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.George Tidmarsh, a biopharma veteran and adjunct professor at Stanford's medical school, has been appointed as the new head of the FDA's Center for Drug Evaluation and Research (CDER). His extensive industry experience will be valuable in his new government position. Data secrecy among cell and gene therapy developers is hindering progress in the field, causing fragmentation, stalling innovation, and delaying access to treatments. Meanwhile, Sarepta is facing challenges with its elevidys shipments and has lost platform designation for its technology. At the same time, Roche's phase III trial in COPD has failed, impacting the market path for astegolimab. Layoffs are happening at companies like GSK, Sail, and BioNTech. Experts are exploring new ways to overcome barriers in cell therapy production.Data secrecy among cell and gene therapy developers continues to hinder progress and access to treatments. Acadia has introduced a new team and pipeline with ambitious goals. Patients are fighting for access to Brainstorm's ALS drug after promising real-world data. Moderna's withdrawal of its flu vaccine has left combination flu/COVID-19 vaccines in limbo. In other news, Sarepta is facing challenges with its DMD gene therapy, Ultragenyx's gene therapy for Sanfilippo syndrome is rejected by the FDA, GSK's Blenrep loses an adcomm vote, and BMS' anemia drug Reblozyl fails a Phase III trial. The FDA is experiencing layoffs and employee turnover amid an overhaul. Vinay Prasad overruled reviewers on Moderna's COVID-19 shot for kids. Upcoming events include a webinar on AI for real-world research and job opportunities in the biopharma industry. Readers are encouraged to provide feedback and suggest topics for future coverage.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Bristol Myers Squibb, GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Bristol Myers Squibb, GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Bristol Myers Squibb, GSK, Johnson & Johnson, and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.
欢迎收听雪球出品的财经有深度，雪球，国内领先的集投资交流交易一体的综合财富管理平台，聪明的投资者都在这里。今天分享的内容叫从海外并购看国内疫苗的出海价值，来自userfield。国产疫苗标志性品种的预期变化最近几年，度过新冠疫苗繁荣期的国内疫苗行业迎来了低潮期，无论是HPV疫苗还是带状疱疹疫苗，经营表现并没有给行业带来逻辑增量弹性。1、HPV疫苗智飞生物代理的MSD的HPV疫苗系列，4价疫苗已经大幅缩减，而王牌9价HPV疫苗也开始出现滞销，导致智飞生物的库存高企，甚至让MSD在25H1停止了9价HPV疫苗的发货。万泰生物作为国产第一家9价HPV疫苗，市场本来寄予厚望。在1年多前，9价HPV疫苗多轮访视，预期NDA的时候，市值就顶在800亿级别。但没想到的是，2025年9价HPV疫苗滞销让预期逐步回落，甚至在25年6月出获批的时候，玩了一把“见光死”，获批反而股价下跌！最终，这款国产九价HPV疫苗定价为499元/支，价格约为进口九价HPV疫苗的40%。我们拭目以待，在九价HPV疫苗销售周期高点往下走的阶段里，国产获批带来进一步竞争加剧后的市场格局变化！2、带状疱疹疫苗在新生儿出生率下降背景下，大家对疫苗行业的热点开始转到成人疫苗领域。随着HPV疫苗的成功，大家对带状疱疹疫苗的预期也很高。智飞与GSK签了大额订单合同，百克生物的国产减毒带状疱疹疫苗也获批上市。但随着外部消费疲软，带状疱疹疫苗的销售推广也没那么顺利。我们看到第一次智飞与GSK的合同约定24-26年合同额在200亿，但在24年底修订了补充合同，销售期限从2026年底延长至2034年底，重组带状疱疹疫苗的预计采购金额约为216亿元。同时也看到百克生物只有在带状疱疹上市后三个季度内，还保持不错的销售趋势，然后到了2024-2025年，销售颓势明显。全球疫苗市场的变化1、重磅品种进入成熟期全球TOP级别疫苗的增速都下来了。疫苗一哥9价HPV疫苗，可能在2025年会因为中国市场疲软而出现大幅下滑。潜力疫苗品种RSV疫苗有可能出现昙花一现的趋势，GSK和辉瑞都遇到加强针疗效不佳的问题，无法转变成类似流感疫苗的每年都接种的常规疫苗。2、国产疫苗的跟随趋势对标全球疫苗排行榜，国产疫苗已经完成了大部分重磅疫苗的国产化。万泰拿下了第一个9价HPV疫苗；沃森、康泰、康希诺已经让13价肺炎疫苗充分国产化；多联苗领域，康泰做了百白破-Hib四联苗，并且百白破-IPV-Hib五联苗已经进入临床阶段；带状疱疹疫苗：百克第一个国产化，而绿竹的重组带状疱疹疫苗已经申报上市，有望成为第一家重组带状疱疹疫苗国产企业；RSV疫苗：国内重组、RNA等多个技术路线品种齐头并进，艾棣维欣进度最快，已经完成临床2期，安科生物旗下的阿法纳生物，已经把RSV mRNA疫苗推进到临床2期，而三叶草生物已经完成RSV单苗的澳洲临床1期，现在正在做FDA临床1期，同时在澳洲新开了二联苗和三联盟的临床1期。所以，国产疫苗企业正在做的事情，就是把全球重磅疫苗做到国产化。这些疫苗品种中，虽然无法比肩对标疫苗的全球重磅程度，但是万泰9价HPV疫苗、绿竹的重组带状疱疹等品种，我认为仍然有望成为几十亿的大品种。全球疫苗领域重磅并购1、赛诺菲 32 亿美元收购 Translate2021年，赛诺菲以每股 38 美元现金收购 mRNA 技术公司 Translate Bio，总对价约 32 亿美元。后者专注于传染病 mRNA 疫苗开发，其技术平台被用于开发新冠疫苗及其他传染病疫苗。2、GSK 33 亿美元收购 Affinivax2022年，GSK 以 33 亿美元收购细菌性疫苗公司 Affinivax，其核心资产为多抗原呈递系统技术，可开发覆盖 24 种血清型的新一代肺炎球菌疫苗 AFX 3772。3、阿斯利康 11 亿美元收购 Icosavax2023 年，阿斯利康支付 8.38 亿美元预付款收购病毒样颗粒疫苗公司 Icosavax，若达成里程碑条款，总金额可增至 11 亿美元。后者核心资产为针对呼吸道合胞病毒和人偏肺病毒的双价疫苗 IVX-A12，已进入临床 II 期。4、BioNTech 12.5 亿美元收购 CureVac2025 年，BioNTech 以全股票交易方式收购德国 mRNA 公司 CureVac，交易总价值 12.5 亿美元。CureVac 在 mRNA 骨架优化、个性化癌症疫苗及生产技术方面具有核心能力，其 mRNA 疫苗 CV2CoV 曾用于新冠疫苗开发。从上面梳理的几笔10亿美金以上的疫苗领域并购交易，我们发现要么是买技术平台，要么是买重磅产品，未来疫苗领域的潜力重磅并购估计也是围绕这两个方向。国产疫苗企业BD出海可能性除了重磅疫苗国产化逻辑外，在创新药BD出海大时代，国产疫苗企业是否有望对标各种Biotech完成BD出海？我觉得有机会！对标全球疫苗销售TOP排行榜以及近几年重磅并购交易，我看到的机会来自几个逻辑方向：mRNA新技术突破、海外重磅疫苗补强。1、mRNA疫苗mRNA预防疫苗最先在新冠领域突破，国内也批准的石药的mRNA新冠疫苗。近几年，mRNA疫苗探索其他适应症领域，国产疫苗基于mRNA技术的RSV、带状疱疹等多款疫苗已经推进到临床。全球范围内，Moderna 的mRNA技术RSV疫苗 mRESVIA已经获批。mRNA治疗性疫苗，并不局限于传统疫苗企业，而更像biotech领域。国内mRNA肿瘤疫苗赛道近些年崛起趋势明显！上市公司中，云顶新耀的通用型现货 mRNA 肿瘤疫苗EVM14刚刚完成中美双报，成为公司的另一个核心发展板块。所以，mRNA等新技术领域，无论是预防性疫苗，还是治疗性疫苗，国内药企有望对外技术授权，完成BD出海之举。2、海外疫苗补强对于传统疫苗，国内疫苗企业也正在经历从跟随到超越的过程，部分国产疫苗企业有望补强现有海外重磅疫苗短板，甚至疗效优异成为me better产品。RSV疫苗：GSK和辉瑞的RSV疫苗，都出现了间隔重复接种后无法达到第一针的疗效，就是所谓的加强针疗效不佳。从而也导致了商业化第二年，销售额都出现了下降。两家药企最希望的是把RSV疫苗变成类似流感疫苗的每年都重复接种的品种，这样就从一锤子买卖变成了持续购买逻辑，RSV疫苗才能够真正成为超级重磅品种。三叶草生物的重组RSV疫苗的FDA临床1期，用于验证GSK加强针的有效性。如果临床效果明显，有望解决GSK/辉瑞的RSV疫苗加强针问题，重现15亿美元销售额的辉煌。同时然后三叶草生物的两款RSV联苗，在近期也已经启动澳洲临床1期，其中SCB-1022二联疫苗，有望对标阿斯利康8亿美元收购的Icosavax的核心产品，呼吸道合胞病毒和人偏肺病毒的双价疫苗 IVX-A1；而SCB-1033则是全球首家也是独家的RSV三联苗产品。只不过三叶草的三款RSV系列疫苗，都处于临床1期，不确定比较大。我们只能说，如果能够成功，则有望带来潜在超级BD交易。但一切都还要等25年底的数据揭盲情况。带状疱疹疫苗：绿竹生物是国内进展最快的重组带状疱疹疫苗，现在已经处于NDA阶段，2026年有望上市成为第一个国产重组带状疱疹疫苗。绿竹的重组带状疱疹疫苗，与GSK的Shingrix的头对头试验比较结果看，有更强的细胞免疫反应。绿竹生物的LZ901带状疱疹疫苗，佐剂中不含刺激物，副作用大幅低于Shingrix，这也是GSK带状疱疹的痛点。所以，绿竹生物的重组带状疱疹疫苗，经过2.6万人的大样本临床3期数据，充分说明这款产品的保护率和安全性更好，可能成为GSK带状疱疹Shingrix的me better产品。所以，如果说成熟疫苗产品BD出海，还有可能头对头做出优效的产品，我觉得绿竹生物重组带状疱疹疫苗有可能成为第一个吃螃蟹的疫苗产品。毕竟Shingrix年销售额超过40亿美金，替代市场潜力足够有吸引力。总结疫苗领域，虽然国内需求疲软，但是在创新出海背景下，我们发现虽然国内疫苗技术水平提升，有望成为BD出海的新细分领域。无论是基于新技术的mRNA疫苗方向，还是对标海外重磅疫苗，补短板 or me-better，都可能成为突破点！
New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now supplied in a prefilled syringe.
In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über einen Mega-Deal von Lucid, Billionen-Träume bei Netflix und den Absturz von Jungheinrich. Außerdem geht es um Quantumscape, Bigbear.AI, Aeva Technologies, D-Wave, Archer Aviation, Intuitive Machines, Rocket Lab, AST Spacemobile, Netflix, Disney, ComCast, Warner Brothers Discovery, Uber Technology, Interactive Brokers, TSMC, ASML, PepsiCo, Taiwan Semiconductor, Novartis, Richemont, ABB, Siemens, Salzgitter, Burberry, American Express, Tema Neuroscience and Mental Health ETF (WKN: A408EL), Vertex Pharmaceutical, Eisai, Biogen, Eli Lilly, DexCom, Siemens Healthineers, Johnson&Johnson, Pfizer, Lindbeck, GSK, Atai Life Science, Mind Medicine, iShares Core MSCI World (A0RPWH), Xtrackers MSCI World USD (A1XB5U), Vanguard FTSE All-World USD (A2PKXG), Xtrackers AI & Big Data (A2N6LC), Amundi MSCI World USD (ETF146), Amundi Core Stoxx Europe 600 (LYX0Q0), iShares MSCI ACWI (A1JMDF), Xtrackers II EUR Overnight (DBX0AN), WisdomTree Europe Defence ETF (A40Y9K), HanETF Future of Defence ETF (A3EB9T). Habt Ihr suizidale Gedanken, oder habt Ihr diese bei einem Angehörigen/Bekannten festgestellt? Hilfe bietet die Telefonseelsorge: Anonyme Beratung erhält man rund um die Uhr unter den kostenlosen Nummern 0800 / 111 0 111 und 0800 / 111 0 222. Auch eine Beratung über das Internet ist möglich unter http://www.telefonseelsorge.de. Eine Liste mit bundesweiten Hilfsstellen findet sich auf der Seite der Deutschen Gesellschaft für Suizidprävention. Wir freuen uns über Feedback an aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html
Host: Rick Grobbee Guest: Gerhard Hindricks Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1810?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
This episode covers: Cardiology This Week: A concise summary of recent studies ICD Indications in primary prevention Drug treatment of cardiac amyloidosis Mythbusters Host: Rick Grobbee Guests: Carlos Aguiar, Gerhard Hindricks, Marianna Fontana Want to watch that episode? Go to: https://esc365.escardio.org/event/1810 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English-language always prevails. Declarations of interests: Stephan Achenbach, Rick Grobbee, Gerhard Hindricks and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Marianna Fontana has declared to have potential conflicts of interest to report: consultancy for Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium. Research grants from: Alnylam, Bridgbio, Astrazeneca, Pfizer. Share options in LexeoTherapeutics and shares in Mycardium. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
In Teil 2 geht es um den entscheidenden Durchbruch im Fall des Golden State Killers. DNA-Spuren führen zu der Erkenntnis, dass ein einziger Täter hinter den Vergewaltigungen, Einbrüchen und Morden steckt. Ahnenforschung und Stammbäume halfen dabei den Täter endlich zu identifizieren. Außerdem sprechen wir über Michelle McNamara, ihr Buch „I'll Be Gone in the Dark“ und wie sie mit ihren Recherchen und Theorien den Fall neu ins Rollen brachte. Zum Schluss blicken wir auf das Leben des GSK und den Prozess, in dem die Opfer und Angehörigen endlich Gehör fanden. +++ Euch gefällt unser Podcast und ihr wollt uns unterstützen? Dann gebt uns gerne einen Kaffee aus: ko-fi.com/tellmemordpodcast Folgt uns gerne auch auf Instagram (@tellmemordpodcast) für mehr Content zu den Fällen! +++ Alle Infos zu unseren Werbepartnern & Rabattcodes unter: https://linktr.ee/tellmemordpodcast
Ben Plumley is joined by Professor Heidi Larson, Co-founder and Chair of the Global Listening Project (GLP), and Susie Barnes, Senior Vice President of Global Medical Affairs for the Vaccines Division at GSK to discuss the importance of building trust and motivating awareness about new technologies in global health. The conversation covers the collaboration between the GLP and GSK, insights from their research on trust during COVID-19, and how community engagement and innovative communication strategies play a crucial role in vaccine confidence and public health. They emphasize the need for holistic approaches to prevention and the challenges of addressing vaccine hesitancy in an evolving technological landscape. 00:00 Introduction and Podcast Overview 00:45 Episode Topic: Building Trust in New Technologies 01:09 Meet the Guests: Professor Heidi Larson and Susie Barnes 02:31 The Global Listening Project and GSK Partnership 03:44 Impact of COVID-19 on Trust and Vaccine Confidence 07:22 The Role of General Practitioners and Community Health Workers 14:41 Advancements in Vaccine Technology and Prevention 19:16 Communication Strategies in the 21st Century 28:04 AI and the Need for Multiple Listening Strands 28:42 Engaging Communities in Healthcare 29:21 The Future of Therapeutic Relationships 30:58 Challenges in Vaccine Access and Trust 33:27 Communicating Science Effectively 36:06 Global Listening Project Insights 37:38 Understanding Measles and Immune Amnesia 39:39 Balancing Individual Rights and Societal Responsibilities 42:11 Next Steps for the Global Listening Project 46:43 GSK's Commitment to Prevention and Partnership
© 2020-2025 Ivy Podcast Discovery LLC
